search
Back to results

Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy

Primary Purpose

Uterine Fibroids, Adenomyosis, Pelvic Pain

Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
PBS
TLH _adnexal preservation
Sponsored by
University Magna Graecia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Uterine Fibroids focused on measuring Total Laparoscopic Hysterectomy, TLH, Ovarian reserve, Prophylactic bilateral salpingectomy, Ovarian cancer prevention, Ovarian cancer, Fallopian Tubes

Eligibility Criteria

35 Years - 50 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Indication to laparoscopic hysterectomy
  • Accomplished reproductive desire

Exclusion Criteria:

  • Patients with a family history of ovarian cancer and with a known mutation of the BRCA1/2 genes
  • Patients with a current or a past history of cancer
  • Patients who don't consent to the prophylactic salpingectomy
  • Previous adnexal surgery
  • PCOS
  • Estrogen-progestin therapy in the 2 months prior to the enrollment
  • Acute or chronic pelvic inflammatory disorders
  • Malignant gynecological neoplasms
  • Prior chemotherapy or radiotherapy
  • Autoimmune diseases, chronic, metabolic, endocrine and systemic disorders, including hyperandrogenism, hyperprolactinemia, diabetes mellitus and thyroid disease
  • Hypogonadotropic hypogonadism
  • Taking medications that can cause menstrual irregularities
  • Other clinical conditions

Sites / Locations

  • Chair of Obstetrics and Gynecology - University division - UMGRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

TLH_plus_PBS

TLH _adnexal preservation

Arm Description

TLH plus PBS

Standard TLH without PBS

Outcomes

Primary Outcome Measures

Ovarian reserve modification
Ovarian reserve modification will be defined as the difference (expressed as Δ) between post-operative and pre-operative values of AMH, FSH, AFC, OV, VI, FI and VFI

Secondary Outcome Measures

Operative time
Time from skin incision to skin closure
variation of hemoglobin level
postoperative hospital stay
postoperative return to normal activity
complication rate

Full Information

First Posted
March 9, 2014
Last Updated
November 17, 2016
Sponsor
University Magna Graecia
search

1. Study Identification

Unique Protocol Identification Number
NCT02086344
Brief Title
Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy
Official Title
The Effect in Term of Ovarian Reserve Modification of Adding Prophylactic Bilateral Salpingectomy (PBS) to TLH for Preventing Ovarian Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
November 2016
Overall Recruitment Status
Unknown status
Study Start Date
February 2014 (undefined)
Primary Completion Date
December 2016 (Anticipated)
Study Completion Date
December 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Magna Graecia

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of this RCT of study is to compare the standard TLH with adnexal preservation with TLH plus prophylactic bilateral salpingectomy (PBS) in terms of ovarian reserve and surgical outcomes
Detailed Description
Ovarian cancer accounts for 3% of all female cancers and represents the fifth leading cause of cancer death in the Western world (1). In 90% of cases, these are epithelial ovarian cancers (2). Because of the biological aggressiveness of this tumor and nonspecific symptoms, that causes a diagnosis at an advanced stage in 75% of cases, ovarian cancer is the gynecological cancer with the highest mortality rate (3). To date, an effective screening strategy to the early diagnosis of ovarian cancer doesn't exist, so the prophylactic adnexectomy is the only available tool to reduce the incidence and the mortality rate, even if the role of this surgical strategy is controversial, especially in premenopausal women (4). In fact, the American College of Obstetricians and Gynaecologists (ACOG) guidelines recommend the ovarian preservation in premenopausal women with no family history or other risk factors for ovarian cancer (5). Some clinical studies have shown that the prophylactic adnexectomy and the consequent surgical menopause increase significantly the long term risk of cardiovascular and psychosexual diseases. (6-8). In particular, a case-control study done in a population of 29,380 women subjected to hysterectomy with and without adnexectomy, showed an increased risk of total mortality ( HRs 1.12 95 % CI 1:03 to 1:21 ), lethal and non- lethal cardiovascular disease ( HRs 1.17 95 % CI 1:02 to 1:35 ) and stroke ( HRs 1.14 95 % CI 0.98-1.33 ) (9) . In this population of women subjected to salpingectomy, the surgery wasn't able to lead to an improvement in general survival (10). Considering the new histopathological classification of the epithelial ovarian cancer, proposed by Kurman (11) and based on new acquisitions about the pathogenesis and the origin of these tumors, it is possible to conceive a new preventive strategy associated with a less morbidity. In fact, the carcinogenesis model proposed by Kurman, provides for the classification of the most important histological types of epithelial tumors into two types, diversified according to clinico-pathological and genetic features. The type I is composed of low-grade serous, low-grade endometrioid, clear cell and mucinous carcinomas, whose the ovarian borderline tumors and endometriosis represent the pre-neoplastic lesions. Conversely, the II type includes high-grade endometrioid carcinomas, carcinosarcomas and undifferentiated carcinomas and, more frequently, high-grade serous carcinomas, whose preneoplastic lesion, now, seems to be represented by the serous tubal intraepithelial carcinoma (STIC). Plenty of evidence, to support the correlation between the epithelial ovarian cancer and the STIC, has been obtained by immunohistochemical and molecular genetics investigations (11). However, from a clinical point of view, this association has been demonstrated only by a study on 55 patients affected by a high-grade serous carcinoma, whose results have shown an involvement in the endosalpinx in 70% of cases and the presence of STIC in about 50% of cases (12). Some studies, performed on BRCA1 / 2 populations, showed the presence of strongly sites reactive to p53, defined "p53 signature", in the distal tube (13). These sites seem to be more frequent and characteristically multifocal in those tubes with concomitant STIC (14). The finding of "p53 signature" may, therefore, identify an early clonal expansion of the neoplastic proliferation. This new theory has given the opportunity to prevent this devastating type of cancer by the addition of the prophylactic bilateral salpingectomy (PBS, with the only removal of the tube and the preservation of the ovaries) in all surgical procedures performed in those women with benign diseases once they have accomplished their reproductive desire. The PBS, in place of the current standard procedure (bilateral salpingo-oophorectomy) could reduce the risk of cancer, improving at the same time the quality of life and reducing the risk of premature death due to cardiovascular disease, seen in women subjected to salpingo-oophorectomy before the onset of natural menopause. Our preliminary data (17) show that, if the bilateral salpingectomy is performed with great care, no patient has negative effects in terms of ovarian function. In addition, in our experience, no perioperative complication is attributable to salpingectomy alone. Despite the retrospective design of our first study, according to the post hoc analysis, these data have shown a significant statistical reliability. However, prospective data on the effetc of PBS in patients submitted to TLH are still needed

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Uterine Fibroids, Adenomyosis, Pelvic Pain, Pelvic Prolapse
Keywords
Total Laparoscopic Hysterectomy, TLH, Ovarian reserve, Prophylactic bilateral salpingectomy, Ovarian cancer prevention, Ovarian cancer, Fallopian Tubes

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
167 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
TLH_plus_PBS
Arm Type
Experimental
Arm Description
TLH plus PBS
Arm Title
TLH _adnexal preservation
Arm Type
Active Comparator
Arm Description
Standard TLH without PBS
Intervention Type
Procedure
Intervention Name(s)
PBS
Other Intervention Name(s)
Bilateral Salpingectomy
Intervention Description
TLH plus PBS
Intervention Type
Procedure
Intervention Name(s)
TLH _adnexal preservation
Other Intervention Name(s)
Standard TLH without salpingectomy
Intervention Description
TLH without PBS
Primary Outcome Measure Information:
Title
Ovarian reserve modification
Description
Ovarian reserve modification will be defined as the difference (expressed as Δ) between post-operative and pre-operative values of AMH, FSH, AFC, OV, VI, FI and VFI
Time Frame
Three months after laparoscopy
Secondary Outcome Measure Information:
Title
Operative time
Description
Time from skin incision to skin closure
Time Frame
The same day of surgery
Title
variation of hemoglobin level
Time Frame
two hours after the end of surgery
Title
postoperative hospital stay
Time Frame
The day of patient discharge
Title
postoperative return to normal activity
Time Frame
two months after surgery
Title
complication rate
Time Frame
The day of patient discharge

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Indication to laparoscopic hysterectomy Accomplished reproductive desire Exclusion Criteria: Patients with a family history of ovarian cancer and with a known mutation of the BRCA1/2 genes Patients with a current or a past history of cancer Patients who don't consent to the prophylactic salpingectomy Previous adnexal surgery PCOS Estrogen-progestin therapy in the 2 months prior to the enrollment Acute or chronic pelvic inflammatory disorders Malignant gynecological neoplasms Prior chemotherapy or radiotherapy Autoimmune diseases, chronic, metabolic, endocrine and systemic disorders, including hyperandrogenism, hyperprolactinemia, diabetes mellitus and thyroid disease Hypogonadotropic hypogonadism Taking medications that can cause menstrual irregularities Other clinical conditions
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Fulvio Zullo
Phone
39337947003
Email
zullo@unicz.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fulvio Zullo
Organizational Affiliation
Magna Graecia University of Catanzaro
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Roberta Venturella
Organizational Affiliation
Magna Graecia University of Catanzaro
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chair of Obstetrics and Gynecology - University division - UMG
City
Catanzaro
State/Province
CZ
ZIP/Postal Code
88100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fulvio Zullo
Phone
39337947003
Email
zullo@unicz.it
First Name & Middle Initial & Last Name & Degree
Roberta Venturella, MD
First Name & Middle Initial & Last Name & Degree
Daniela Lico, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
23558052
Citation
Morelli M, Venturella R, Mocciaro R, Di Cello A, Rania E, Lico D, D'Alessandro P, Zullo F. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere. Gynecol Oncol. 2013 Jun;129(3):448-51. doi: 10.1016/j.ygyno.2013.03.023. Epub 2013 Apr 2.
Results Reference
background

Learn more about this trial

Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy

We'll reach out to this number within 24 hrs